BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26464626)

  • 1. Expression of alpha B crystallin and BCL2 in patients with infiltrating ductal carcinoma.
    Kim MS; Lee HW; Jun SY; Lee EH
    Int J Clin Exp Pathol; 2015; 8(8):8842-56. PubMed ID: 26464626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
    Zhao P; Lu Y; Jiang X; Li X
    Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer.
    Ayadi EZ; Cherif B; Ben Hamed Y; Mokni M; Rebai A; Ayadi H; Jlidi R
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3557-3564. PubMed ID: 30583683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COX2 overexpression is a prognostic marker for Stage III breast cancer.
    Kim HS; Moon HG; Han W; Yom CK; Kim WH; Kim JH; Noh DY
    Breast Cancer Res Treat; 2012 Feb; 132(1):51-9. PubMed ID: 21533532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
    Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LETM1 overexpression is correlated with the clinical features and survival outcome of breast cancer.
    Li N; Zheng Y; Xuan C; Lin Z; Piao L; Liu S
    Int J Clin Exp Pathol; 2015; 8(10):12893-900. PubMed ID: 26722481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer.
    Chen CY; Yang CY; Chen YC; Shih CW; Lo SS; Lin CH
    BMC Cancer; 2016 Aug; 16(1):697. PubMed ID: 27577936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gli1 is a potential cancer stem cell marker and predicts poor prognosis in ductal breast carcinoma.
    Ni W; Yang Z; Qi W; Cui C; Cui Y; Xuan Y
    Hum Pathol; 2017 Nov; 69():38-45. PubMed ID: 28965964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients.
    Castiglione F; Sarotto I; Fontana V; Destefanis M; Venturino A; Ferro S; Cardaropoli S; Orengo MA; Porcile G
    Anticancer Res; 1999; 19(5C):4555-63. PubMed ID: 10650810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological significance of ARID1B in breast invasive ductal carcinoma.
    Shao F; Guo T; Chua PJ; Tang L; Thike AA; Tan PH; Bay BH; Baeg GH
    Histopathology; 2015 Nov; 67(5):709-18. PubMed ID: 25817822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the molecular chaperone αB-crystallin in infiltrating ductal breast carcinomas and the significance thereof: an immunohistochemical and proteomics-based strategy.
    Kabbage M; Trimeche M; Ben Nasr H; Hammann P; Kuhn L; Hamrita B; Chaieb A; Chouchane L; Chahed K
    Tumour Biol; 2012 Dec; 33(6):2279-88. PubMed ID: 22972503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p16INK4a/p53 in Tunisian patients with breast carcinoma.
    Karray-Chouayekh S; Baccouche S; Khabir A; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
    Acta Histochem; 2011 Sep; 113(5):508-13. PubMed ID: 20598349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
    Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
    Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of HOXD13 expression in human breast cancer.
    Zhong ZB; Shan M; Qian C; Liu T; Shi QY; Wang J; Liu Y; Liu Y; Huang YX; Pang D
    Int J Clin Exp Pathol; 2015; 8(9):11407-13. PubMed ID: 26617867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical Expression of B Cell Lymphoma2 with Clinicopathological Correlation in Triple Negative Breast Cancers in Northern Pakistan.
    Zubair M; Hashmi SN; Afzal S; Muhammad I; Din HU; Ahmed R
    Asian Pac J Cancer Prev; 2016; 17(7):3619-22. PubMed ID: 27510019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast.
    Qian L; Gao X; Huang H; Lu S; Cai Y; Hua Y; Liu Y; Zhang J
    Oncotarget; 2017 Mar; 8(13):21444-21453. PubMed ID: 28423522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
    Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
    Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast.
    Treré D; Montanaro L; Ceccarelli C; Barbieri S; Cavrini G; Santini D; Taffurelli M; Derenzini M
    Ann Oncol; 2007 Jun; 18(6):1004-14. PubMed ID: 17372162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
    Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
    Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.